CARLINK TECH (02531): Zhang Shize is appointed as joint company secretary and legal process agent.
Guanglian Technology Holdings (02531) announces that Mr. Wu Dongcheng has resigned from the position of joint company secretary; and in accordance with Chapter 622 of the Hong Kong Companies Ordinance and Rule 19.05(2) of the Securities Listing Rules of the Hong Kong Stock Exchange, the Hong Kong legal process agent who receives legal documents and notices on behalf of the company in Hong Kong, all resignations will take effect from May 18, 2026. Mr. Zhang Shize will replace Mr. Wu Dongcheng as the joint company secretary and legal process agent, effective from May 18, 2026. Mr. Zhang Yong will continue to serve as the other joint company secretary.
CARLINK TECH (02531) announces that Mr. Wu Dongcheng has resigned from the position of Joint Company Secretary, and in accordance with Section 16 of Chapter 622 of the Companies Ordinance of Hong Kong and Rule 19.05(2) of the Listing Rules of Hong Kong Stock Exchange, as the Hong Kong Legal Process Agent for receiving legal process documents and notices on behalf of the company in Hong Kong, all resignations will take effect from May 18, 2026. Mr. Zhang Shize will replace Mr. Wu Dongcheng as the Joint Company Secretary and Legal Process Agent, effective from May 18, 2026. Mr. Zhang Yong will continue to serve as the other Joint Company Secretary.
Related Articles
US Stock Market Move | The phase III trial of melanoma drug did not reach the primary endpoint, causing Regeneron Pharmaceuticals, Inc. (RENG.US) to drop more than 10% in early trading.
AIM VACCINE (06660): Wen Jie Resigns as Independent Non-executive Director.
CH BIOTECH SER (08037) intends to sell the entire equity of Standard Pathology Laboratory and Jockey Health for a total of HK$3.5 million
US Stock Market Move | The phase III trial of melanoma drug did not reach the primary endpoint, causing Regeneron Pharmaceuticals, Inc. (RENG.US) to drop more than 10% in early trading.
AIM VACCINE (06660): Wen Jie Resigns as Independent Non-executive Director.
CH BIOTECH SER (08037) intends to sell the entire equity of Standard Pathology Laboratory and Jockey Health for a total of HK$3.5 million
